FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed compound relates to novel biaryl-meta-pyrimidine, corresponding to structure (A) and their pharmaceutically acceptable salts. In structure (A): 
X is selected from group consisting of bond O, and CH2, and Y represents bond; or X and Y together can represent bond; each R1 and R2 independent on each other are selected from group consisting of H and unsubstituted C1-C6alkyl; each of p, q, r, n, m independent on each other represents integer number 0 or 1; G0 is selected from group consisting from N and CH; each G represents independently CH, N, CR6 or C, when bound with X, on condition that not more than two groups of G represent N, and each R6 does not depend on another R6; R5 represents methyl, 
Values of other radicals are given in the invention formula.
EFFECT: compounds possess inhibiting activity with respect to family of JAK kinases, in particular JAK2 kinases, and can be used in treatment of myeloproliferative disease, which results from genetic or protein fusions, as a result of increase of function of kinase from family of JAK kinases in cell signal transmission, as well as in treatment of true polycythemia, primary thrombocytopenia, myeloid fibrosis with myeloid metaplasia, proliferative diabetic retinopathy, cancer or eye diseases.
66 cl, 2 tbl, 246 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAMINOTRIAZOLE COMPOUNDS USED AS PROTEIN KINASE INHIBITORS | 2005 |
|
RU2443700C2 |
| MEDICAL USE OF PYRROLOPYRIMIDINE COMPOUND AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND | 2019 |
|
RU2810112C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2387653C2 |
| PYRIMIDINE-SUBSTITUTED PURINE COMPOUNDS AS KINASE(S) INHIBITORS | 2009 |
|
RU2506264C2 |
| APPLICATION OF MEDICATIONS, BINDING EDG-RECEPTOR, IN TREATMENT OF CANCER DISEASE | 2008 |
|
RU2426555C2 |
| PYRROLOPYRIMIDINES USED AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2434871C2 |
| PYRIMIDINE-SUBSTITUTED PURINE DERIVATIVES, PHARMACEUTICAL COMPOSITION BASED THEREON, METHOD OF PROTEIN KINASE INHIBITION, METHOD OF TREATING OR PREVENTING DISEASES SENSITIVE TO PROTEIN KINASE INHIBITION AND METHOD OF TREATING PROLIFERATIVE DISEASES | 2008 |
|
RU2518098C2 |
| HETEROCYCLIC IMMUNOMODULATORS AS INHIBITOR OF IMMUNE RESPONSE CHECKPOINTS PDL1 | 2020 |
|
RU2824127C2 |
| TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF ITS USE | 2020 |
|
RU2747991C1 |
| TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS FOR USE THEREOF | 2015 |
|
RU2715421C2 |
